跳至主要内容
临床试验/NL-OMON50986
NL-OMON50986招募中3 期

A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism - PARTUM

The University of Calgary0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • ONE (or more) First Order Criterion:
  • 1. Known inherited thrombophilia prior to enrolment: Heterozygous factor V
  • heterozygous prothrombin gene variant or protein C deficiency or protein S
  • 2. Antepartum immobilization (strict bedrest) for >=7 days at any time during the
  • OR TWO (or more) Second Order Criteria:
  • 1. Pre-pregnancy BMI >=30 kg/m2
  • 2. Smoking >=5 cigarettes/day pre-pregnancy
  • 3. Previous clinical history of superficial vein thrombosis
  • 4. Pre-eclampsia (SBP >=140 and/or DBP >=90 mmHg on at least one occasion and
  • proteinuria of >=0.3 grams/24 hours or >=30 mg/mmol on a random urine sample)
  • 5. Current pregnancy ending in stillbirth (fetal loss >20 weeks gestation)
  • 6. Emergency cesarean birth (emergency = not planned)
  • 7. Small-for-gestational-age infant at time of delivery (<3rd percentile
  • adjusted for
  • gestational age and sex using the standardized international INTERGROWTH
  • 8. Postpartum infection (symptoms/signs and documented fever and laboratory
  • evidence of infection)
  • 9. Postpartum hemorrhage (>1000 mL regardless of delivery mode)

排除标准

  • 1. More than 48 hours since delivery of the placenta at the time of
  • randomization
  • 2. Received more than 2 doses of LMWH since delivery of the placenta*
  • 3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by
  • their physician and/or local investigator. May include but is not limited to:
  • a. Documented history of provoked or unprovoked VTE
  • b. Mechanical heart valve(s)
  • c. Known antiphospholipid syndrome (APS) (according to the revised
  • Sapporo/Sydney criteria)
  • Pilot PARTUM Trial Version 1.5 08Jun2020
  • d. Known high-risk inherited thrombophilia
  • i. Antithrombin deficiency (two abnormal and no normal tests based on
  • local laboratory cutoffs)
  • ii. Homozygous factor V Leiden (genotyping result required)
  • iii. Homozygous prothrombin gene mutation (genotyping result required)
  • iv. Compound heterozygosity factor V Leiden and prothrombin gene
  • mutation (genotyping result required)
  • v. More than 1 thrombophilia: any combination of 2 or more: factor V
  • Leiden, prothrombin gene mutation, protein C deficiency, protein S
  • deficiency, as previously defined.
  • 4. Need for postpartum ASA as judged by their physician and/or local
  • investigator. May
  • include but is not limited to:
  • a. Documented history of myocardial infarction
  • b. Documented history of ischemic stroke or transient ischemic attack (TIA)
  • 5. Contraindication to ASA including**:
  • a. History of known ASA allergy
  • b. Documented history of a gastrointestinal ulcer
  • c. Known platelet count <50 x 109/L at any time during the current pregnancy or
  • d. Active bleeding at any site, excluding normal vaginal bleeding, at the time
  • randomization
  • e. Most recent known hemoglobin <=70 g/L during the current pregnancy or
  • f. Known severe hypertension (SBP >200 mmHg and/or DBP >120 mmHg) during
  • the current pregnancy or postpartum
  • 6. <18 years of age
  • 7. Unable or refused consent
  • *Pneumatic compression devices or graduated compression stockings are not a
  • contraindication to enrolment but will be recorded.
  • **Postpartum non-steroidal anti-inflammatories NSAID) use is not a
  • contraindication to
  • enrolment but will be recorded.

研究者

发起方
The University of Calgary

相似试验